Dimethyl fumarate
| Clinical data | |
|---|---|
| Other names | DHF; trans-1,2-Ethylenedicarboxylic acid dimethyl ester; (E)-2-Butenedioic acid dimethyl ester |
| License data | |
| Routes of administration | Oral |
| Drug class | Immunomodulator |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.009.863 |
| Chemical and physical data | |
| Formula | C6H8O4 |
| Molar mass | 144.126 g·mol−1 |
| 3D model (JSmol) | |
| Density | 1.37 g/cm3 g/cm3 |
| Melting point | 103.5 °C (218.3 °F) |
| Boiling point | 193 °C (379 °F) |
| |
| |
| (verify) | |
Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. Dimethyl fumarate combined with three other fumaric acid esters (FAEs) is solely licensed in Germany as an oral therapy for psoriasis (brand name Fumaderm). Since 2013, it has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with relapsing multiple sclerosis (brand name Tecfidera). In 2017, an oral formulation of dimethyl fumarate (brand name Skilarence) was approved for medical use in the European Union as a treatment for moderate-to-severe plaque psoriasis. Dimethyl fumarate is thought to have immunomodulatory properties without causing significant immunosuppression.
Dimethyl fumarate has also been applied as a biocide in furniture or shoes to prevent growths of mold during storage or transport in humid climates. However, due to cases of allergic reactions after skin contact, dimethyl fumarate-containing consumer products are no longer authorised to be manufactured (since 1998) or imported (since 2009) in the European Union. Dimethyl fumarate is available as a generic medication.